Literature DB >> 24093674

Semaphorin3E-induced inflammation contributes to insulin resistance in dietary obesity.

Ippei Shimizu1, Yohko Yoshida, Junji Moriya, Aika Nojima, Akiyoshi Uemura, Yoshio Kobayashi, Tohru Minamino.   

Abstract

Semaphorins and their receptors (plexins) are axon-guiding molecules that regulate the development of the nervous system during embryogenesis. Here we describe a previously unknown role of class 3 semaphorin E (Sema3E) in adipose tissue inflammation and insulin resistance. Expression of Sema3E and its receptor plexinD1 was upregulated in the adipose tissue of a mouse model of dietary obesity. Inhibition of the Sema3E-plexinD1 axis markedly reduced adipose tissue inflammation and improved insulin resistance in this model. Conversely, overexpression of Sema3E in adipose tissue provoked inflammation and insulin resistance. Sema3E promoted infiltration of macrophages, and this effect was inhibited by disrupting plexinD1 expression in macrophages. Disruption of adipose tissue p53 expression led to downregulation of Sema3E expression and improved adipose tissue inflammation. These results indicate that Sema3E acts as a chemoattractant for macrophages, with p53-induced upregulation of Sema3E expression provoking adipose tissue inflammation and systemic insulin resistance in association with dietary obesity.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24093674     DOI: 10.1016/j.cmet.2013.09.001

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  50 in total

Review 1.  Role of innate and adaptive immunity in obesity-associated metabolic disease.

Authors:  Tracey McLaughlin; Shelley E Ackerman; Lei Shen; Edgar Engleman
Journal:  J Clin Invest       Date:  2017-01-03       Impact factor: 14.808

2.  Deep phenotyping in zebrafish reveals genetic and diet-induced adiposity changes that may inform disease risk.

Authors:  James E N Minchin; Catherine M Scahill; Nicole Staudt; Elisabeth M Busch-Nentwich; John F Rawls
Journal:  J Lipid Res       Date:  2018-05-23       Impact factor: 5.922

Review 3.  Inflammation, metaflammation and immunometabolic disorders.

Authors:  Gökhan S Hotamisligil
Journal:  Nature       Date:  2017-02-08       Impact factor: 49.962

Review 4.  Semaphorins and plexins as therapeutic targets.

Authors:  Thomas Worzfeld; Stefan Offermanns
Journal:  Nat Rev Drug Discov       Date:  2014-08       Impact factor: 84.694

5.  Semaphorin-3E attenuates intestinal inflammation through the regulation of the communication between splenic CD11C+ and CD4+ CD25- T-cells.

Authors:  Laëtitia Kermarrec; Nour Eissa; Hongxing Wang; Kunal Kapoor; Abdoulaye Diarra; Abdelilah S Gounni; Charles N Bernstein; Jean-Eric Ghia
Journal:  Br J Pharmacol       Date:  2019-04-01       Impact factor: 8.739

Review 6.  Netrins & Semaphorins: Novel regulators of the immune response.

Authors:  Jordyn Feinstein; Bhama Ramkhelawon
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-09-14       Impact factor: 5.187

7.  Silibinin ameliorates Aβ25-35-induced memory deficits in rats by modulating autophagy and attenuating neuroinflammation as well as oxidative stress.

Authors:  Xiaoyu Song; Biao Zhou; Lingyu Cui; Di Lei; Pingping Zhang; Guodong Yao; Mingyu Xia; Toshihiko Hayashi; Shunji Hattori; Yuko Ushiki-Kaku; Shin-Ichi Tashiro; Satoshi Onodera; Takashi Ikejima
Journal:  Neurochem Res       Date:  2016-12-22       Impact factor: 3.996

8.  Semaphorin3E/plexinD1 Axis in Asthma: What We Know So Far!

Authors:  Latifa Koussih; Abdelilah S Gounni
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 9.  The role of the semaphorins in cancer.

Authors:  Gera Neufeld; Yelena Mumblat; Tatyana Smolkin; Shira Toledano; Inbal Nir-Zvi; Keren Ziv; Ofra Kessler
Journal:  Cell Adh Migr       Date:  2016-08-17       Impact factor: 3.405

Review 10.  The role of the p53 tumor suppressor in metabolism and diabetes.

Authors:  Che-Pei Kung; Maureen E Murphy
Journal:  J Endocrinol       Date:  2016-09-09       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.